New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 13, 2014
16:08 EDTPDIIPDI, Inc. subsidiary acquires miRInform test assets from Asuragen
PDI, Inc. announced that its Interpace Diagnostics subsidiary has entered the expanding cancer molecular diagnostics market with the acquisition of the miRInform Thyroid and Pancreas cancer test assets from privately held Asuragen. This acquisition marks the execution of PDI's strategy to create a commercially driven molecular diagnostics business and a commitment to developing new solutions for the thyroid and pancreatic cancer testing markets. This transaction includes the miRInform Thyroid and Pancreas tests, intellectual property related to these and other tests in development for thyroid cancer, and an extensive 5,000 plus tissue sample biobank to support life cycle management efforts. Terms of the transaction include $8M in upfront cash, future commercial milestone-based payments and royalties.
News For PDII From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 17, 2014
09:14 EDTPDIIPDI, Inc. subsidiary laucnhes cancer risk assessment test
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use